Why Thrombo-Embolism is a Percutaneous First Treatment in 2025

Disclosure(s):

Gary M. Ansel, MD, FACC: akura medical: Consultant (Ongoing); BSC: Consulting Fees (e.g., advisory boards) (Ongoing); Cook Medical: Consultant (Ongoing), royalties (Ongoing); Efemoral Medical, Inc.: Stock-privately held company (Ongoing); Healthcare inroads: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); medtronic.: Consulting Fees (e.g., advisory boards) (Ongoing); mercator: Consultant (Terminated, April 1, 2024); Otsuka Pharmaceuticals: Consultant (Ongoing); Reflow Medical: Consulting Fees (e.g., advisory boards) (Ongoing); sentante: Consultant (Ongoing); surmodics: royalties (Ongoing)